A single intravenous ketamine infusion significantly reduced depression symptoms in patients within four hours compared to a placebo. The treatment also dramatically lowered suicidal thoughts within 24 hours. Patients reported fewer depressive symptoms after one week and reduced suicidal thoughts for up to a month.
Researchers from the University of Connecticut School of Medicine reviewed 26 clinical trials involving more than 1,100 patients. Approximately 626 received ketamine while 540 served as controls. Most trials focused on major depressive disorder though 11.5 percent included bipolar depression and 7.7 percent covered both unipolar and bipolar diagnoses.
Lead author Taeho Greg Rhee of the University of Connecticut School of Medicine stated that when existing treatments fail patients with severe depression could consider ketamine infusions. He described it as a safer option than electroconvulsive therapy.
Ketamine works rapidly by blocking glutamate a neurotransmitter that can negatively impact emotions when levels run too high in the brain. Traditional antidepressants raise serotonin levels gradually often taking weeks to show full effects. The findings point to two key uses: life-saving intervention in emergency rooms for suicidal ideation and repeated sessions for those with treatment-resistant depression.
Major depressive disorder affects approximately 280 million people globally. For some patients symptoms persist despite multiple therapies leading to higher risks of suicide attempts and death.
Rhee noted that while intravenous ketamine lacks FDA approval for depression it may be used off-label for severe cases or those at high risk of suicidal behaviors. Experts stress administration only in closely monitored clinic settings to ensure safety.
The most common adverse effects included headaches numbness dissociation nausea dizziness and visual disturbances. These proved temporary resolving within hours of infusion. Rarer serious events such as hospitalization suicide attempts and suicide occurred but most were unrelated to ketamine.
Dr. Lama Bazzi a New York City psychiatrist not involved in the study has treated several patients with ketamine infusions. She said that for a small subset experiencing major depressive episodes or suicidal thoughts intravenous ketamine can be genuinely lifesaving. The relief feels almost immediate providing distance from intense emotions.
Researchers acknowledged limitations including small sample sizes that may magnify effects and the challenge of applying results to broader populations. Some patients might have guessed they received ketamine influencing symptom reports. Long-term outcomes remain unstudied, though Bazzi believes that when patients are severely depressed or suicidal, ketamine is sometimes the only choice that almost always works.
Rhee emphasized that ketamine should only be used medically due to risks of abuse and addiction. He stresses careful medical supervision given potential risks.
Bazzi cautioned that the medication requires administration in monitored clinical environments. Anyone considering alternative depression treatments should consult a doctor first. The review highlights ketamine as one tool among options rather than a cure-all.
Patients facing treatment-resistant depression now have evidence of an option that acts within hours instead of weeks.
Patients interested in ketamine infusions should discuss options with their physicians to determine suitability and ensure proper oversight. The concrete data from over 1,100 trial participants offers a measurable path forward for those who have exhausted standard antidepressants. One infusion's effects lasting up to a month could provide critical breathing room before follow-up care begins.
A single intravenous ketamine infusion significantly reduced depression symptoms in patients within four hours compared to a placebo. The treatment also dramatically lowered suicidal thoughts within 24 hours. Patients reported fewer depressive symptoms after one week and reduced suicidal thoughts for up to a month.
Researchers from the University of Connecticut School of Medicine reviewed 26 clinical trials involving more than 1,100 patients. Approximately 626 received ketamine while 540 served as controls. Most trials focused on major depressive disorder though 11.5 percent included bipolar depression and 7.7 percent covered both unipolar and bipolar diagnoses.
Lead author Taeho Greg Rhee of the University of Connecticut School of Medicine stated that when existing treatments fail patients with severe depression could consider ketamine infusions. He described it as a safer option than electroconvulsive therapy. The analysis appeared in May in JAMA Psychiatry.
Ketamine works rapidly by blocking glutamate a neurotransmitter that can negatively impact emotions when levels run too high in the brain. Traditional antidepressants raise serotonin levels gradually often taking weeks to show full effects. The findings point to two key uses: life-saving intervention in emergency rooms for suicidal ideation and repeated sessions for those with treatment-resistant depression.
Major depressive disorder affects approximately 280 million people globally. For some patients symptoms persist despite multiple therapies leading to higher risks of suicide attempts and death. Almost all patients relapsed after a single infusion underscoring the need for ongoing treatment.
Rhee noted that while intravenous ketamine lacks FDA approval for depression it may be used off-label for severe cases or those at high risk of suicidal behaviors. Experts stress administration only in closely monitored clinic settings to ensure safety.
The most common adverse effects included headaches numbness dissociation nausea dizziness and visual disturbances. These proved temporary resolving within hours of infusion. Rarer serious events such as hospitalization suicide attempts and suicide occurred but most were unrelated to ketamine.
Dr. Lama Bazzi a New York City psychiatrist not involved in the study has treated several patients with ketamine infusions. She said that for a small subset experiencing major depressive episodes or suicidal thoughts intravenous ketamine can be genuinely lifesaving. The relief feels almost immediate providing distance from intense emotions.
Researchers acknowledged limitations including small sample sizes that may magnify effects and the challenge of applying results to broader populations. Some patients might have guessed they received ketamine influencing symptom reports. Long-term outcomes remain unstudied though Bazzi believes it works when patients feel severely depressed or suicidal.
Rhee emphasized that ketamine should only be used medically due to risks of abuse and addiction. Dr. Marc Siegel Fox News senior medical analyst has observed increasing medical and recreational ketamine use. He stresses careful medical supervision given potential risks.
Bazzi cautioned that the medication requires administration in monitored clinical environments. Anyone considering alternative depression treatments should consult a doctor first. The review highlights ketamine as one tool among options rather than a cure-all.
The study connects to broader challenges in mental health care where access to timely effective treatments can mean the difference between life and death for those in crisis. Patients facing treatment-resistant depression now have evidence of an option that acts within hours instead of weeks.
Patients interested in ketamine infusions should discuss options with their physicians to determine suitability and ensure proper oversight. The concrete data from over 1,100 trial participants offers a measurable path forward for those who have exhausted standard antidepressants. One infusion's effects lasting up to a month could provide critical breathing room before follow-up care begins.
Highlighted text was flagged by the council. Tap to see feedback.
